GlassScriptPhysician profile
Ashley Davis
NPI 1972031581
$3,901.85
in general payments reported to CMS, 2019-2025
23 companies · $2,354 in 2025
The $2,354 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,548 · 2025: $2,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,866 · Education: $35.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,865.89 |
| Education | $35.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,007.59 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $538.67 | 2024-2025 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $345.17 | 2024-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $264.94 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $254.30 | 2024-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $236.89 | 2024-2025 | Ibsrela |
| Braintree Laboratories, INC. | $186.38 | 2024-2025 | Suflave, Sutab |
| Gilead Sciences, INC. | $158.03 | 2024-2025 | |
| Qol Medical, LLC | $153.16 | 2025 | Sucraid |
| Lilly USA, LLC | $140.52 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $124.27 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $76.03 | 2025 | Dupixent |
| Pfizer INC. | $68.17 | 2024-2025 | |
| Celltrion USA INC. | $59.31 | 2024-2025 | Zymfentra, Vegzelma |
| Genzyme Corporation | $52.34 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $43.79 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $40.05 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $33.81 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $30.97 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $25.48 | 2024 | Rebyota |
| Amgen INC. | $23.40 | 2025 | Uplizna |
| Celgene Corporation | $20.10 | 2024 | Zeposia |
| Capsovision, INC. | $18.48 | 2025 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.